For sure the partnerships add moving parts to any deal as do the RVX royalty preferreds, if they go with the deal. Certainly no big problem though, acquiring assets that have inherent partnerships is done all the time. Perhaps a good example here would be when Pfizer aquired Medivation ($14B USD) and in so doing aquired a 50% partnership with Astellas in Xtandi (the driver of the deal).  Zenith is working with both Pfizer and Astellas currently.